Glenmark Pharmaceuticals has filed a statement of claim with the American Arbitration Association against Napo Pharmaceuticals Inc seeking a declaration that Glenmark’s distribution rights to develop, commercialize and distribute Croferlemer in 140 countries for treatment of diarrhoel diseases includes the exclusive rights to distribute through relief agencies in these countries. The company in order to prevent Napo from distributing products into Glenmark's Territories has filed the case.
Croferlemer is a novel, first in class anti-diarrhoeal agent that has a physcological mechanism of action that is different compared to traditional anti- diarrhoeal agents. Besides, its potential efficacious role in multiple diarrhoeal agents, Croferlemer controls diarrhea with no known drug-drug interaction, minimal systemic adsorption and, unlike, current anti-diarrhoeal agents. No serious side effects, and can be used chronically.
The company has an exclusive license from Napo to develop, commercialize and distribute Croferlemer in 140 countries for specific indications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: